NeOnc Technologies Holdings, Inc., a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers, has announced a significant milestone in its strategic partnership with Quazar Investment. The company has executed a Sub-License Agreement, transferring rights from NeOnc to its Abu Dhabi subsidiary, NuroCure, covering the UAE and the wider GCC and MENA regions for its innovative NEO100 and NEO212 treatments. This agreement is part of a larger $50 million equity investment and expansion plan into the MENA region, as outlined in a non-binding term sheet. The partnership aims to drive institutional capital, enhance market liquidity, and support the launch of clinical trials and infrastructure development across the region. The completion of this partnership is contingent upon meeting several conditions, including the legal establishment of NuroMENA and NuroCure in Abu Dhabi and finalizing necessary offering documents.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.